1. Home
  2. > Pharmaceutical Market Trends
China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

  • September 2022
  • 3000 pages
  • ID: 6323530
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

• Research Methodology
• China Bispecific Antibodies Market Sales Opportunity To Double By 2028
• Approved Bispecific Antibodies In China: 3 Antibodies
• 3 to 4 Bispecific Antibodies Are Further Expected To Enter the Market Over Next 5 Years
• Comprehensive Insight On Ongoing Bispecific Antibodies Clinical Trials By Phase, Company, Indication & Patient Segment
• Bispecific Antibodies Trials In China: > 250 Antibodies
• Comprehensive Insight On More Than 80 Bispecific Antibodies Available For Licensing/Partnership
• China Bispecific Antibodies Market Dynamics
• Insight On Key Chinese Companies Developing Bispecific Antibodies

With a rapid increase in the clinical research and development activities in the recent years, China has developed as one of the biggest pharmaceutical markets in the world. With R&D activities covering various therapeutic areas and diseases, it has also emerged as one of the most popular destinations for holding clinical trials. Learning from their international counterparts, companies in China have shifted their focus from manufacturing generic drugs to the development of innovative drugs and therapies. One of the most recent developments in China’s pharma market was the progress it made in the treatment of cancer – specifically after the introduction of immunotherapy in the targeted cancer research scenario.

Immunotherapy has become one of the most sought after oncology treatments in recent years. China was slow to enter this market but ever since it did, its progress has been massive. Bispecific antibodies are one of the most popular immunotherapies in China, whose development has been riding on the tailcoats of the success and acceptance of monoclonal antibodies in the region. Currently the global bispecific antibodies R&D pipeline is packed with over 800 antibodies in ongoing clinical trials out of which more than 250 clinical trials are being held in China, which enunciates its new-found reputation in the pharma market.

At present, there are 3 bispecific antibodies which have got approval by China’s drug approval authority, the National Medical Products Administration. These are Blincyto, Hemlibra and Cadonilimab. Out of these three, Cadonilimab is the only bispecific antibody which was developed independently and solely by domestic researchers at Akeso which shows China still has a lot to learn seeing its dependence on western companies for the growth of its bispecific antibodies market. On the brighter side, pharma companies in China have started developing their own proprietary technologies which make use of the latest advancements in the applied science sector. YBODY®, CRIBTM, ITabTM, and FIT-Ig are some platforms which have been developed by some Chinese companies, while others like Legend Biotech have theirs under development.

Some of the major players in China’s bispecific antibody market include Biopharma, EpimAb, Alphamab Oncology and BeiGene. BeiGene was granted the license by Amgen to commercialize its FDA-approved Blincyto in the region. The breadth of applications of bispecific antibodies has long expanded beyond the oncology segment. Researchers in China are now testing their effects on autoimmune diseases, as well as inflammatory diseases. Many major pharma companies are now involved in developing these therapies.

The Amgen-BeiGene partnership is just one of innumerable collaborations that are taking place between domestic and western companies which are enabling the growth of China’s bispecific antibody market with the introduction of world-class technologies and the engagement of highly skilled and knowledgeable researchers. With more pharma companies trying to set foot in the Chinese bispecific antibodies market, more companies are signing agreements and partnerships to get access to proprietary platforms, the use of which consequently reduces the resources it would have had to put in the process on its own.

With the government constantly trying to encourage the development of innovative drugs in the country by bringing in new policies and making amendments to already existing regulations, more pharma companies are getting encouraged to enter the immunotherapy market. Some of the incentives include tax exemptions and the setting up of business parks in various major cities to help them grow as centers for pharma companies. The Zhangjiang region of Shanghai already houses research facilities of Novartis, GlaxoSmithKline and Roche which has helped the region to grow as an industrial hub. The government has aptly realized the benefits that come along with western companies and has thus made newer policies for a smoother entry of western companies in the domestic market and an easier approval process for developed drugs that use clinical trial data from other countries. The government’s designation of drugs as breakthrough or priority has substantially shortened the approval time. The entire process takes a little over 3 years in China now compared to 12 in the US.

With multiple factors in play, China’s bispecific antibody market and its immunotherapy markets are undoubtedly expected to grow in the coming years as the number of companies, both local and domestic, trying to enter the nation has increased several folds because of the many possibilities, rich opportunities and favorable incentives in the region’s market, helping China make its place in the largest pharma markets globally.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

US Pharmaceutical Fluid Handling Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Offering, Tubing, Application, Usage, and End User

  • $ 3000
  • November 2022
  • 183 pages

The US pharmaceutical fluid handling market is expected to grow from US$ 3,863.89 million in 2021 to US$ 5,179.71 million by 2028; it is estimated to grow at a CAGR of 4.3% from 2022 to 2028. Rising use ...

  • United States
  • Pharmaceutical
  • Industry analysis
  • Pharmaceutical Production
  • Chronic Disease Prevalence

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on